Private Tepezza (teprotumumab) infusion cost

A private Tepezza (teprotumumab) infusion is estimated at £15,500 to £25,500 per infusion in the UK, all-inclusive at CQC-registered infusion centres. The standard 8-infusion course over about 24 weeks totals £124,000 to £204,000. The licensed biologic drug cost is by far the dominant component, typically more than 95% of the total. The fee also covers the consultant assessment, audiometric and glycaemic surveillance, and monitored IV administration.

What is Tepezza (teprotumumab)?

Teprotumumab (brand name Tepezza) is a fully human monoclonal antibody that binds the insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts, blocking the IGF-1R / TSH-receptor complex that drives orbital tissue remodelling in thyroid eye disease (TED). It reduces proptosis, double vision and clinical activity in active moderate-to-severe disease. It was FDA-approved in January 2020 on the basis of the phase 2 trial and the OPTIC phase 3 trial, in which 83% of patients were proptosis responders at week 24 versus 10% on placebo, with a mean proptosis reduction of around 3 mm — comparable to surgical decompression.

Teprotumumab received MHRA marketing authorisation in May 2025, the first medicine licensed in the UK specifically for adults with moderate-to-severe thyroid eye disease. It is a prescription-only medicine given under specialist supervision. The established NHS first-line treatment for active TED remains pulsed IV methylprednisolone under the EUGOGO protocol, and NHS access to teprotumumab depends on local commissioning; it is also available privately. For patients who are not suitable for, or do not wish to pursue, Tepezza, surgical orbital decompression and squint (strabismus) surgery address proptosis and diplopia respectively.

Tepezza prices

Tepezza is dosed by body weight (10 mg/kg for the first infusion, 20 mg/kg thereafter), given every 3 weeks for 8 infusions. The drug-vial cost dominates the price; the wide range reflects body weight and the number of vials needed.

Because teprotumumab is a high-cost biologic, the vial cost dominates the total and a written quotation is confirmed at assessment. See the wider oculoplastics price list and the full price list for surgical alternatives.

What’s included in the price

A quality private Tepezza package should include:

• A consultant oculoplastic and endocrinology assessment to confirm active moderate-to-severe TED and suitability
• Baseline orbital imaging where indicated
• Baseline and surveillance pure-tone audiometry to monitor for hearing loss
• Baseline and surveillance fasting glucose and HbA1c to monitor for hyperglycaemia
• The teprotumumab vials (MHRA-licensed biologic), body-weight dosed
• The IV infusion administration over about 60 to 90 minutes with cardiopulmonary monitoring and post-infusion observation
• Structured 3-weekly cycle scheduling across the 24-week course

The drug-vial cost is the dominant component, typically more than 95% of the total course price.

What affects the price

Several factors move a Tepezza quote within the per-infusion and course ranges:

• Body weight — dosing is weight-based (10–20 mg/kg), so heavier patients need more vials.
• Drug cost — the licensed biologic vial cost drives most of the total.
• Number of infusions — the standard course is 8 infusions; a second OPTIC-X course doubles the drug cost.
• Surveillance intensity — diabetic patients and those with hearing risk need closer monitoring.
• Site of care — central London infusion centres sit at the upper end of the range.

Now that teprotumumab is MHRA-licensed, insurer positions vary; some policies may consider the drug and others cover only the consultant assessment and surveillance — always confirm in writing, and see our guidance for insured patients.

Frequently asked questions